23andMe Holding Co. (ME)
Market Cap | 235.57M |
Revenue (ttm) | 247.99M |
Net Income (ttm) | -521.97M |
Shares Out | 482.92M |
EPS (ttm) | -1.11 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 656,765 |
Open | 0.522 |
Previous Close | 0.510 |
Day's Range | 0.520 - 0.548 |
52-Week Range | 0.401 - 2.320 |
Beta | 1.29 |
Analysts | Strong Buy |
Price Target | 3.88 (+614.29%) |
Earnings Date | Feb 7, 2024 |
About ME
23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliat... [Read more]
Financial Performance
In 2022, ME's revenue was $299.49 million, an increase of 10.15% compared to the previous year's $271.89 million. Losses were -$311.66 million, 43.3% more than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ME stock is "Strong Buy." The 12-month stock price forecast is $3.88, which is an increase of 614.29% from the latest price.
News
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been...
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
Built upon peer-reviewed published science, the Historical Matches feature weaves customers' ancestral connections into the story of human history and migration Built upon peer-reviewed published scie...
Fed-up 23andMe users lash out at the company, accusing it of scamming them into auto-renewal
23andMe users say the company charged them for subscription renewals they had cancelled. The FTC released over a hundred customer complaints to Gizmodo.
23andMe Launches New Genetic Reports on Common Forms of Cancer
23andMe customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (PRS) developed by 23andMe ...
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6 and mechanism of 23ME-01473, and new non-clini...
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
NEW YORK, NY / ACCESSWIRE / February 27, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed ...
23andMe Holding Co (NASDAQ:ME) Jewish and Chinese Users
NEW YORK, NY / ACCESSWIRE / February 26, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed ...
23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users
NEW YORK, NY / ACCESSWIRE / February 22, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed ...
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
NEW YORK, NY / ACCESSWIRE / February 21, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed ...
‘There are no serious safeguards': can 23andMe be trusted with our DNA?
The at-home genetic testing company is dealing with financial woes and a security breach. What does that mean for customers?
Hackers got nearly 7 million people's data from 23andMe. The firm blamed users in ‘very dumb' move
The company pointed at people who ‘failed to update their passwords' as sensitive data was offered for sale on forums
DATA BREACH- 23andMe Jewish & Chinese Consumers May be Affected
NEW YORK, NY / ACCESSWIRE / February 9, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed c...
23andMe considers splitting up company to revive stock price
23andMe reported dismal third-quarter fiscal 2024 results and discussed splitting itself in two to help juice its stock price.
23andMe shares slide more than 15% as lower services revenue hits Q3 results
Shares of 23andMe Holding Co. fell 15.8% Thursday after the DNA-testing company fiscal third-quarter sales declined 33%, weighed down by lower consumer services and research revenue.
23andMe Reports Third Quarter Fiscal 2024 Financial Results
Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473 Announced new non-exclu...
23andMe's share price keeps on falling in the wake of hacks and losses
23andMe stock is down over 95% from its peak, cutting its value from $6 billion to $345 million. The genetic-testing company is facing financial and strategic challenges, and was hacked last year.
As the 23andMe (ME) stock price implodes, here's the silver lining
23andMe (NASDAQ: ME) stock price has had a spectacular collapse and is at risk of being booted from NASDAQ. After peaking at over $16 in 2021, the stock has dropped to just 71 cents, making it one of ...
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced the U.S. Food and Drug Admi...
23andMe Launches Month-Long Initiative to Amplify ARRAY's “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
“Seat 16” program allows audiences to share the critically acclaimed film with teens across the country “Seat 16” program allows audiences to share the critically acclaimed film with teens across the ...
23andMe Breach Targeted Jewish and Chinese Customers, Lawsuit Says
The class-action suit said the genetic testing company failed to notify customers whose personal information was compiled into “curated” lists that were sold on the dark web.
23andMe admits it didn't detect cyberattacks for months
In a data breach notification letter filed with regulators this weekend, 23andMe revealed that hackers started breaking into customers' accounts in April 2023 and continued through most of September.
23andMe to Report FY2024 Third Quarter Financial Results
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, ...
Moneta Gold and Nighthawk Gold Announce the Proposed Directors for the MergeCo Board
TORONTO--(BUSINESS WIRE)---- $ME.to #gold--Nighthawk Gold Corp. (“Nighthawk”) (TSX: NHK) and Moneta Gold Inc. (TSX: ME)(OTCQX: MEAUF)(FSE: MOPA) (“Moneta”) (together with Nighthawk, “MergeCo”) announc...
23andMe blames users for data breach, citing recycled passwords
Home DNA testing firm 23andMe is placing the blame on customers who reused login credentials for a cyber incident in which 6.9 million customers' data was exposed.
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
Thirty additional patients with advanced neuroendocrine and advanced ovarian cancer will be enrolled in the study of 23ME-00610, an investigational antibody targeting CD200R1